Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, Philippe; L. Garfall, Alfred; W.C.J. van de Donk, Niels; Nahi, Hareth; F. San Miguel, Jesús; Oriol, Albert; K. Nooka, Ajay; G. Martin, Thomas; Rosiñol, Laura; Chari, Ajai; Karlin, Lionel; Benboubker, Lotfi; Mateos, María‐Victoria; J. Bahlis, Nizar; Popat, Rakesh; Besemer, Britta; Martínez‐López, Joaquín; Sidana, Surbhi; Delforge, Michel; Pei, Lixia; Trancucci, Danielle; Verona, Raluca; Girgis, Suzette; Xin Wang Lin, Shun; Olyslager, Yunsi; Jaffe, Mindy; Uhlar, Clarissa; Stephenson, Tara; Van Rampelbergh, Rian; Banerjee, Arnob; D. Goldberg, Jenna; Kobos, Rachel; Krishnan, Amrita; Z. Usmani, Saad

doi:10.1056/nejmoa2203478

Public

Teclistamab in Relapsed or Refractory Multiple Myeloma

Published in New England Journal of Medicine • Jun 5, 2022

Authors:

Philippe Moreau

Alfred L. Garfall

Niels W.C.J. van de Donk

Abstract

BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients ...

Subject

Multiple myeloma

Refractory (planetary science)

Antibody

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!